This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Abbott Laboratories(ABT - Get Report) was downgraded at Deutsche Bank from buy to hold. Valuation call, based on a $33 price target, Deutsche said.
Aruba Networks(ARUN) was upgraded at Stifel Nicolaus from hold to buy. $27 price target. Growth could re-accelerate in 2013, Stifel Nicolaus said.
The Bank of New York Mellon(BK - Get Report) was downgraded at Citigroup to neutral from buy. Valuation call, Citi said.
BancorpSouth(BXS) was downgraded at Keefe, Bruyette & Woods from market perform to underperform. Valuation call, based on a $12 price target, KBW said.
Cardinal Health(CAH) was upgraded at Mizuho from neutral to buy. $46 price target. Company will likely renew two major contracts in 2013, Mizuho said.
Continental Resources(CLR) was initiated with a buy rating at Deutsche Bank. $94 price target. Solid Bakken position can continue to drive growth, Deutsche said.
Cepheid(CPHD) was downgraded at Piper Jaffray from overweight to neutral. $34 price target. See further downside potential to near-term results, Piper Jaffray said.
Endo Pharmaceuticals(ENDP) was downgraded at Piper Jaffray from overweight to neutral. Opana ER is facing generic competition, Piper Jaffray said. $28 price target.
Esco Technologies(ESE) was upgraded at Robert Baird from neutral to outperform. $52 price target. Company should see higher orders in the near term, Robert Baird said.
Edwards Lifesciences(EW) was initiated with a market perform rating at JMP Securities. Company trades at a premium to its peers but has limited upside earnings potential, JMP said.
East West Bancorp(EWBC) was upgraded at Sterne Agee to buy from neutral. $26 price target. Earnings power from expense management, Sterne Agee said.
FactSet Research Systems(FDS) was initiated at Goldman Sachs with a sell rating. $79 price target. Slowing growth and emerging competition, Goldman said.
Freescale(FSL) was downgraded at JP Morgan to neutral. Company could see lower demand and lacks near-term catalysts, JP Morgan said.
Illumina(ILMN) was upgraded at Piper Jaffray from neutral to overweight. $61 price target. Company can continue to gain market share in next-generation sequencing, Piper Jaffray said.
Johnson & Johnson(JNJ - Get Report) was upgraded at Deutsche Bank to buy. $82 price target. Company has a diversified business and deserves to trade at a premium valuation, Deutsche said.